Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles.

BackgroundThe evolving landscape of oncology treatment, particularly in the realm of multiple myeloma immunotherapy, presents new challenges and opportunities for healthcare providers and, of note, nurses. Innovative treatments like chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies have revolutionized care for patients with relapsed and refractory multiple myeloma.ObjectivesThis article underscores the role of nurses in managing care transitions, emphasizing their responsibilities in patient education, coordination of care, and the seamless handoff between treatment phases.MethodsThrough a review of existing literature and knowledge gained from expert opinions and experiences, this article presents recommendations for nurses managing care transitions.FindingsEffective transitions of care optimize patient outcomes, minimize barriers to access, and ensure continuity of care for patients undergoing complex treatments like CAR T-cell therapy and bispecific antibodies. These therapies require meticulous coordination during transitions of care.